Gut Bacterial Molecule Promotes Kidney Fibrosis in Diabetes
New research reveals that a molecule produced by gut bacteria, corisin, plays a crucial role in promoting kidney fibrosis in diabetic patients. Blocking corisin could offer a novel approach to prevent kidney failure.
Recent research highlights the role of a molecule produced by gut bacteria in accelerating kidney fibrosis, a severe complication of diabetes that often leads to kidney failure. Scientists from the University of Illinois Urbana-Champaign and Mie University in Japan identified that a small peptide called corisin, generated by Staphylococcus bacteria in the gut, travels through the bloodstream attached to albumin, a common blood protein. Once reaching the kidneys, corisin detaches and triggers cellular aging and death within kidney tissues, setting off a chain of inflammation and scar tissue formation.
The study found elevated levels of corisin in the blood and urine of patients with diabetic kidney fibrosis, with the amount correlating directly to the severity of kidney damage. In mouse experiments, introducing antibodies that neutralize corisin significantly slowed the progression of kidney damage, suggesting the molecule plays a critical role in disease development.
Corisin’s journey from the gut to the kidneys was elucidated through computer simulations and laboratory experiments, revealing that it binds to albumin and exploits this transport mechanism to reach renal tissues. When corisin reaches the kidney, it accelerates aging processes in kidney cells, leading to increased inflammation, cell death, and fibrosis.
Current treatments for diabetic kidney fibrosis mainly control blood sugar and blood pressure but do not halt or reverse scarring. The discovery of corisin as a key driver opens new possibilities for targeted therapies, such as antibody treatments to block its activity. Researchers are now planning further testing in more advanced animal models, including pigs, with the hope of developing human applications.
This groundbreaking finding advances our understanding of how gut bacteria influence distant organs and underscores the potential for microbiome-targeted interventions in preventing or slowing kidney fibrosis in diabetes. Future therapies aimed at blocking molecules like corisin could significantly improve patient outcomes and quality of life.
Source: https://medicalxpress.com/news/2025-08-kidney-fibrosis-linked-molecule-gut.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Both Artificially Sweetened and Sugary Drinks Increase Risk of Liver Disease, New Study Finds
New research shows that both sugary and artificially sweetened drinks are linked to increased risk of liver disease, highlighting the importance of healthier beverage choices for liver health.
CDC Withdraws Vaccine Presentation After Citation Error Discovered
The CDC has withdrawn a vaccine safety presentation after discovering that the cited study, claiming long-term brain effects from a preservative, did not exist, raising concerns over misinformation in public health communications.
Addressing Firefighter Cancer Risks: Partnership with Biotech for Early Detection
Firefighters face a higher risk of cancer, but new partnerships with biotech firms aim to improve early detection and save lives through advanced MRI screenings.
AI Innovation Enables Detection of Fatty Liver Disease via Chest X-Rays
Innovative AI model analyzes routine chest X-rays to detect fatty liver disease, offering a cost-effective and accessible diagnostic method that could transform early screening strategies.